EA200000718A1 - Композиции целекоксиба - Google Patents

Композиции целекоксиба

Info

Publication number
EA200000718A1
EA200000718A1 EA200000718A EA200000718A EA200000718A1 EA 200000718 A1 EA200000718 A1 EA 200000718A1 EA 200000718 A EA200000718 A EA 200000718A EA 200000718 A EA200000718 A EA 200000718A EA 200000718 A1 EA200000718 A1 EA 200000718A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
tselekoksiba
cyclooxygenase
mediator
disorders
Prior art date
Application number
EA200000718A
Other languages
English (en)
Other versions
EA003363B1 (ru
Inventor
Данчен Гао
Антони Дж. Хлинак
Ахмад М. Мажари
Джеймз Э. Трулов
Маргарет Б.Вудхалл Вон
Original Assignee
Дж.Д.Сирл Энд Ко.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22332446&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200000718(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дж.Д.Сирл Энд Ко. filed Critical Дж.Д.Сирл Энд Ко.
Publication of EA200000718A1 publication Critical patent/EA200000718A1/ru
Publication of EA003363B1 publication Critical patent/EA003363B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)

Abstract

Предлагаются фармацевтические композиции, содержащие одну или несколько единиц дозировки для перорального употребления, каждая из которых содержит целекоксиб в виде частиц в количестве от приблизительно 10 до приблизительно 1000 мг в однородной смеси с одной или несколькими фармацевтически приемлемыми добавками. Композиции полезны при лечении или профилактике заболеваний и расстройств, в которых медиатором является циклооксигеназа-2.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000718A 1998-11-30 1999-11-30 Дискретная твердая единица дозировки фармацевтической композиции для перорального употребления, включающая в себя целекоксиб (варианты), и способ лечения заболевания или расстройства у пациента, которому показано лечение ингибитором циклооксигеназы-2 EA003363B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11033398P 1998-11-30 1998-11-30
PCT/US1999/028411 WO2000032189A1 (en) 1998-11-30 1999-11-30 Celecoxib compositions

Publications (2)

Publication Number Publication Date
EA200000718A1 true EA200000718A1 (ru) 2001-04-23
EA003363B1 EA003363B1 (ru) 2003-04-24

Family

ID=22332446

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000718A EA003363B1 (ru) 1998-11-30 1999-11-30 Дискретная твердая единица дозировки фармацевтической композиции для перорального употребления, включающая в себя целекоксиб (варианты), и способ лечения заболевания или расстройства у пациента, которому показано лечение ингибитором циклооксигеназы-2

Country Status (48)

Country Link
US (4) US20050267189A1 (ru)
EP (1) EP1049467B1 (ru)
JP (1) JP3563036B2 (ru)
KR (2) KR20040065307A (ru)
CN (2) CN1299683C (ru)
AP (1) AP1637A (ru)
AR (1) AR020015A1 (ru)
AT (1) ATE225650T1 (ru)
AU (1) AU748851B2 (ru)
BG (1) BG64938B1 (ru)
BR (1) BR9908030A (ru)
CA (1) CA2319201C (ru)
CR (2) CR6210A (ru)
CU (1) CU20000176A7 (ru)
DE (1) DE69903404T2 (ru)
DK (1) DK1049467T3 (ru)
EA (1) EA003363B1 (ru)
EE (1) EE04834B1 (ru)
ES (1) ES2185412T3 (ru)
GC (1) GC0000114A (ru)
GE (1) GEP20022784B (ru)
GT (1) GT199900203A (ru)
HK (2) HK1035144A1 (ru)
HN (1) HN1999000210A (ru)
HR (1) HRP20000434B1 (ru)
HU (1) HUP0100867A3 (ru)
IL (1) IL136532A (ru)
IS (1) IS5555A (ru)
MA (1) MA26709A1 (ru)
ME (1) ME00416B (ru)
NO (1) NO329912B1 (ru)
NZ (1) NZ505762A (ru)
OA (1) OA11616A (ru)
PA (1) PA8486001A1 (ru)
PE (1) PE20001349A1 (ru)
PL (1) PL200957B1 (ru)
PT (1) PT1049467E (ru)
RS (1) RS50158B (ru)
SA (1) SA99191255B1 (ru)
SI (1) SI1049467T1 (ru)
SK (1) SK283510B6 (ru)
TN (1) TNSN99223A1 (ru)
TR (1) TR200002207T1 (ru)
TW (1) TW579295B (ru)
UA (1) UA58576C2 (ru)
UY (2) UY25826A1 (ru)
WO (1) WO2000032189A1 (ru)
ZA (1) ZA200002722B (ru)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CA2357525A1 (en) * 1999-01-27 2000-08-03 Cornell Research Foundation, Inc. Treating cancers associated with overexpression of her-2/neu
BR0008059A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib
EP1150959B1 (en) 1999-12-08 2008-02-27 Pharmacia Corporation Solid-state form of celecoxib having enhanced bioavailability
ATE283048T1 (de) * 1999-12-08 2004-12-15 Pharmacia Corp Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
AU2731401A (en) * 1999-12-22 2001-07-03 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
EP1239857B1 (en) * 1999-12-22 2006-04-19 Pharmacia Corporation Dual-release compositions of a cyclooxygenase-2- inhibitor
MY120279A (en) 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
US20020009421A1 (en) * 2000-06-01 2002-01-24 Wilder Karol J. Therapy following skin injury from exposure to ultraviolet radiation
CA2409123A1 (en) * 2000-06-08 2001-12-13 The University Of Texas System Heterocycle derivatives and methods of use
US6589557B2 (en) * 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
JP2004506680A (ja) * 2000-08-18 2004-03-04 ファルマシア・コーポレーション シクロオキシゲナーゼ−２阻害剤の迅速崩壊経口製剤
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
IN191090B (ru) * 2000-08-29 2003-09-20 Ranbanx Lab Ltd
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
WO2003039472A2 (en) * 2001-11-07 2003-05-15 Pharmacia Corporation Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2003074474A2 (en) 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
CA2479665C (en) † 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BR0309913A (pt) 2002-05-13 2005-06-07 Pharmacia Corp Compósito estável de celecoxib amorfo e processo para fabricar o mesmo
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2003249510A1 (en) * 2002-08-12 2004-02-25 Ranbaxy Laboratories Limited A parenteral dosage form of selective cox-2 inhibitors
US20040186105A1 (en) * 2002-08-30 2004-09-23 Allenspach Carl T. Pharmaceutical composition exhibiting consistent drug release profile
HUE033042T2 (en) 2002-11-22 2017-11-28 Gruenenthal Gmbh Combination of selected analgesics with COX II inhibitors
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20060172019A1 (en) * 2003-03-07 2006-08-03 Ralston Stuart H Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
WO2004093814A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
US6916852B2 (en) * 2003-05-12 2005-07-12 University Of Tennessee Research Foundation Method for regulation of microvascular tone
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
SI1742922T1 (sl) * 2004-04-01 2016-07-29 Zoetis Serivices Llc Kristalinični pirazolni derivat
US20080248957A1 (en) * 2004-09-09 2008-10-09 Bayer Healthcare Ag Pharmaceutical Composition
EP1833476A1 (en) 2004-11-23 2007-09-19 PLIVA HRVATSKA d.o.o. Extended release pharmaceutical composition of celecoxib
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
TWI394753B (zh) 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
WO2008106059A1 (en) * 2007-02-26 2008-09-04 Merck & Co., Inc. Formulations for cathepsin k inhibitors
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US20100233272A1 (en) * 2007-11-15 2010-09-16 Leah Elizabeth Appel Dosage forms comprising celecoxib providing both rapid and sustained pain relief
MX2010009990A (es) 2008-03-11 2010-12-15 Depomed Inc Formas de dosificación gástricas retentivas de liberación prolongada que comprenden combinaciones de un analgésico no opioide y un analgésico opioide.
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CN102317975B (zh) * 2009-02-17 2015-02-04 皇家飞利浦电子股份有限公司 功能成像
PL387415A1 (pl) * 2009-03-06 2010-09-13 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Kompozycja farmaceutyczna zawierająca celekoksyb oraz sposób jej wytwarzania
SG175308A1 (en) * 2009-04-24 2011-11-28 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
KR20160148041A (ko) * 2009-04-24 2016-12-23 아이슈티카 피티와이 리미티드 캅셀화된 나노입자의 상업적 규모의 생산
UA110322C2 (uk) * 2009-04-24 2015-12-25 Iceutica Pty Ltd Спосіб одержання композиції наночастинок біологічно активного матеріалу з високою об'ємною часткою
JP5906181B2 (ja) * 2009-04-24 2016-04-20 イシューティカ ピーティーワイ リミテッド 商業的ナノ粒子及びマイクロ粒子粉末の生産方法
BRPI1013835B8 (pt) * 2009-04-24 2021-05-25 Iceutica Pty Ltd método para produção de material biologicamente ativo de nanopartícula e/ou micropartícula, composição compreendendo referido material, composição farmacêutica, uso da mesma, e, método para produção de uma composição farmacêutica, de um produto veterinário e de um produto agrícola
CA2762388A1 (en) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Oral compositions of celecoxib
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
WO2011050944A1 (en) 2009-10-28 2011-05-05 Ratiopharm Gmbh Formulations containing celecoxib
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
EP2340818A1 (en) * 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of venlafaxine and celecoxib
EP2340819A1 (en) * 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising venlafaxine and celecoxib in the treatment of pain
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
CN102000018B (zh) * 2010-02-09 2012-07-04 浙江大学宁波理工学院 一种含塞来昔布的固体分散物及其制备方法和应用
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20140093563A1 (en) * 2011-06-13 2014-04-03 Ranbaxy Laboratories Limited Febuxostat compositions
CN102949403A (zh) * 2011-08-24 2013-03-06 天津药物研究院 一种塞来昔布组合物及制备方法和用途
CN102949402A (zh) * 2011-08-24 2013-03-06 天津药物研究院 一种塞来昔布组合物及制备方法和用途
CN102920676B (zh) * 2012-12-04 2014-08-20 山东省立医院 一种塞来昔布咀嚼片及其制备方法
CN103989657B (zh) * 2013-02-20 2016-10-05 四川国为制药有限公司 一种含有塞来昔布的胶囊剂
WO2014143031A1 (en) * 2013-03-15 2014-09-18 The Penn State Research Foundation Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
CN103230382B (zh) * 2013-04-17 2015-12-09 贵州联盛药业有限公司 塞来昔布泡腾片及其制备方法
CN103585164B (zh) * 2013-11-08 2015-12-02 海南合瑞制药股份有限公司 一种溶出度增加的塞来昔布固体组合物及其制备方法和应用
CN104027319A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 一种塞来昔布分散片及其制备方法
KR101652332B1 (ko) 2014-10-31 2016-09-01 (주) 킴스제약 관절염 치료용 혼합조성물 및 관절염 치료용 혼합제제의 제조방법
CN104721146A (zh) * 2015-04-03 2015-06-24 海南海力制药有限公司 塞来昔布溶剂分散体、微丸胶囊及其制备方法
EP3302429A1 (en) * 2015-05-28 2018-04-11 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
KR101710792B1 (ko) 2015-07-14 2017-02-28 주식회사 유영제약 세레콕시브 및 트라마돌을 함유하는 약제학적 조성물
CN104983714A (zh) * 2015-08-06 2015-10-21 苏州二叶制药有限公司 一种塞来昔布胶囊及其制备方法
CN105125520A (zh) * 2015-09-29 2015-12-09 深圳瑞多力泰医药科技实业有限公司 一种塞来昔布制剂及其制备方法和控制方法
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
CN105343030A (zh) * 2015-12-16 2016-02-24 钟柏根 一种塞来昔布胶囊及其制备方法
KR101625344B1 (ko) 2015-12-21 2016-06-08 주식회사 유영제약 세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물
US20170348419A1 (en) * 2016-06-06 2017-12-07 NuBioPharma, LLC Oral liquid suspensions
KR102002906B1 (ko) * 2016-10-18 2019-07-23 경동제약 주식회사 셀레콕시브를 포함하는 정제
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
WO2020214791A1 (en) * 2019-04-18 2020-10-22 Nangenex Nanotechnology Incorporated Celecoxib compositions and methods for their use
CN110604722B (zh) * 2019-09-19 2020-12-11 山东创新药物研发有限公司 一种塞来昔布的固体分散方法及塞来昔布胶囊的制备方法
IL294033A (en) * 2020-01-16 2022-08-01 Eisai R&D Man Co Ltd Medicinal substance of lamborexant and medical preparation containing it
CN112263562B (zh) * 2020-09-25 2022-09-30 石药集团欧意药业有限公司 一种塞来昔布胶囊组合物的制备方法
CN112933085B (zh) * 2020-12-28 2021-12-21 中以海德人工智能药物研发股份有限公司 一种化合物在制备治疗或预防病毒性肝炎用药物中的应用
CN113402463B (zh) * 2021-07-08 2023-12-26 江南大学 一种塞来昔布微晶、负载塞来昔布微晶的温敏性凝胶及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5644A (en) * 1848-06-20 Improvement in apparatus for the increase of the speed of vessels
EP0001247A1 (en) 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
EP0078430B2 (de) * 1981-10-29 1993-02-10 Bayer Ag Verfahren zur Herstellung von festen, schnellfreisetzenden Arzneizubereitungen mit Dihydropyridinen
IT1206166B (it) * 1984-07-26 1989-04-14 Sigma Tau Ind Farmaceuti Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US5266581A (en) 1984-07-04 1993-11-30 Bayer Aktiengesellschaft Solid composition containing dihydropyridine, PVP and PVPP
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US5112619A (en) 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4971790A (en) 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
DE3610037A1 (de) * 1986-03-21 1987-09-24 Schering Ag Nifedipinkombinationspraeparat
FR2602423B1 (fr) 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
IT1201136B (it) * 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
GB8702411D0 (en) 1987-02-03 1987-03-11 Zyma Sa Swellable pellets
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
IT1215726B (it) 1988-01-18 1990-02-22 Alfa Wassermann Spa Formulazioni galeniche a cessione programmata.
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US4866848A (en) * 1988-10-24 1989-09-19 Alexander Agelidis Instrument for subdividing angles into halves, thirds or fifths
US5342624A (en) * 1989-02-16 1994-08-30 British Technology Group Ltd. Dispensing device
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5474784A (en) * 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
FR2669915B1 (fr) 1990-11-29 1993-01-29 Atochem Particules de chlorure de magnesium a structure polyedre, composante catalytique supportee sur ces particules, procedes de fabrication de ces produits et des polyolefines obtenues a partir de cette composante catalytique.
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US6048850A (en) 1992-09-22 2000-04-11 Young; Donald A. Method of inhibiting prostaglandin synthesis in a human host
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5540669A (en) * 1993-09-30 1996-07-30 Becton, Dickinson And Company Iontophoretic drug delivery system and method for using same
CN1061036C (zh) * 1993-11-30 2001-01-24 G·D·瑟尔公司 用于治疗炎症的取代的吡唑基苯磺酰胺类化合物
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
CA2180651A1 (en) 1994-01-10 1995-07-13 Yves Ducharme Phenyl heterocycles as cox-2 inhibitors
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
TW493991B (en) 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
RO118200B1 (ro) 1995-05-25 2003-03-28 Gd Searle & Co Chicago Procedeu pentru obtinerea (3-haloalchil-1h-pirazol-1-il)-arilsulfonamidelor
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
IL126899A (en) * 1996-05-17 2004-03-28 Merck & Co Inc Preparations for once-daily treatment of diseases mediated by cyclooxygenase-2
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
KR100212449B1 (ko) * 1996-10-09 1999-08-02 이계철 무궁화 위성방송의 송/수신기 정합 방법
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US20030225150A1 (en) * 1997-04-21 2003-12-04 Pharmacia Corporation Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
BR9809451A (pt) * 1997-05-22 2000-06-20 Searle & Co Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38.
NZ502990A (en) * 1997-08-27 2002-02-01 Hexal Ag Pharmaceutical compositions of meloxicam with improved solubility and bioavailability
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
EA004032B1 (ru) 1998-09-10 2003-12-25 Нюкомед Данмарк А/С Фармацевтические композиции лекарственных веществ с быстрым высвобождением
US6440967B1 (en) * 1998-11-12 2002-08-27 Merck & Co., Inc. Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
AU3596500A (en) 1999-02-19 2000-09-04 Pozen, Inc. Formulation of 5-ht agonists with cox-2 inhibitors

Also Published As

Publication number Publication date
EP1049467A1 (en) 2000-11-08
SK283510B6 (sk) 2003-08-05
AU748851B2 (en) 2002-06-13
EP1049467B1 (en) 2002-10-09
ES2185412T3 (es) 2003-04-16
BG64938B1 (bg) 2006-10-31
US9750756B2 (en) 2017-09-05
EA003363B1 (ru) 2003-04-24
SI1049467T1 (en) 2003-04-30
CN1299683C (zh) 2007-02-14
IL136532A (en) 2003-01-12
AP1637A (en) 2006-07-17
HUP0100867A2 (hu) 2002-03-28
US20150011514A1 (en) 2015-01-08
JP3563036B2 (ja) 2004-09-08
US20080167362A1 (en) 2008-07-10
TW579295B (en) 2004-03-11
DE69903404T2 (de) 2003-08-14
NO20003815L (no) 2000-09-29
WO2000032189A1 (en) 2000-06-08
CR9842A (es) 2008-05-16
BG104680A (en) 2001-02-28
PT1049467E (pt) 2003-02-28
ME00416B (me) 2011-10-10
ZA200002722B (en) 2000-11-29
UA58576C2 (ru) 2003-08-15
KR100501034B1 (ko) 2005-07-18
NO20003815D0 (no) 2000-07-25
US20050267189A1 (en) 2005-12-01
DK1049467T3 (da) 2003-02-10
HN1999000210A (es) 2000-08-23
NO329912B1 (no) 2011-01-24
CN1288378A (zh) 2001-03-21
BR9908030A (pt) 2000-11-28
US20120171284A1 (en) 2012-07-05
UY25826A1 (es) 2001-08-27
AP2000001874A0 (en) 2000-09-30
YU48600A (sh) 2004-07-15
EE200000437A (et) 2001-06-15
HRP20000434B1 (en) 2010-12-31
GEP20022784B (en) 2002-09-25
PA8486001A1 (es) 2000-09-29
OA11616A (en) 2004-09-10
IS5555A (is) 2000-06-30
PL341372A1 (en) 2001-04-09
PL200957B1 (pl) 2009-02-27
HK1035144A1 (en) 2001-11-16
AR020015A1 (es) 2002-03-27
HRP20000434A2 (en) 2000-08-31
PE20001349A1 (es) 2000-11-27
RS50158B (sr) 2009-05-06
NZ505762A (en) 2002-06-28
TNSN99223A1 (fr) 2005-11-10
JP2002531403A (ja) 2002-09-24
SA99191255B1 (ar) 2006-11-25
CU20000176A7 (es) 2005-11-18
GC0000114A (en) 2005-06-29
HUP0100867A3 (en) 2002-05-28
EP1049467A4 (en) 2001-08-08
DE69903404D1 (de) 2002-11-14
SK11062000A3 (sk) 2001-03-12
UY26025A1 (es) 2000-08-21
CA2319201A1 (en) 2000-06-08
CN1537531A (zh) 2004-10-20
CR6210A (es) 2004-05-28
GT199900203A (es) 2001-11-15
HK1069541A1 (en) 2005-05-27
MA26709A1 (fr) 2004-12-20
ATE225650T1 (de) 2002-10-15
TR200002207T1 (tr) 2000-12-21
KR20010040484A (ko) 2001-05-15
CN1154490C (zh) 2004-06-23
AU1838100A (en) 2000-06-19
CA2319201C (en) 2006-07-11
EE04834B1 (et) 2007-06-15
IL136532A0 (en) 2001-06-14
KR20040065307A (ko) 2004-07-21

Similar Documents

Publication Publication Date Title
EA200000718A1 (ru) Композиции целекоксиба
EA200100872A1 (ru) Композиция валдекоксиба
MY115662A (en) Novel compounds with analgesic effect
EA200200806A1 (ru) Предупреждение потери и восстановление костной массы некоторыми агонистами простагландина
ATE357216T1 (de) Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
LU91254I2 (fr) Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA199800805A1 (ru) Пероральная фармацевтическая форма лекарственного препарата в виде множественной дозированной формы с модифицированным высвобождением
EA200200106A1 (ru) Фармацевтическая композиция леводопа/карбидопа/энтакапон
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
PT100514A (pt) 3-aminoquinuclidinas substituidas e composicoes farmaceuticas que qs contem
EA200100870A1 (ru) Композиции-ингибиторы циклооксигеназы-2 с быстро наступающим терапевтическим действием
MY119403A (en) Novel compounds with analgesic effect.
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
DE69710065D1 (de) Androsten-derivate
HUP0301892A2 (hu) Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
SE0102055D0 (sv) New Compounds
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
SE9504662D0 (sv) New compounds
EA200300430A1 (ru) Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
EA200101157A1 (ru) 14β-H-СТЕРОЛЫ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ЭТИХ ПРОИЗВОДНЫХ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, РЕГУЛИРУЮЩИХ МЕЙОЗ
DE69814669T2 (de) Pharmaceutische Zusammensetzung enthaltend (+)-EPHEDRIN und einen H1 Rezeptor Antagonisten

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AZ BY KG TJ TM

MC4A Revocation of a eurasian patent under opposition procedure